Biotechnology News and Research

RSS

iBioLaunch platform technology to be licensed for plant-expressed influenza vaccines project

iBio, Inc. announced today that it has agreed in principle to license its technology, the iBioLaunch™ platform, and provide technology transfer services to G-Con, LLC, a private Texas company, and its affiliates, for the development and manufacture of plant-expressed influenza vaccines at a new facility being constructed in Bryan, Texas. The “GreenVax Project” will show proof of concept for a large-scale vaccine production facility using Nicotiana plants grown hydroponically in a contained environment.

27 Feb 2010

CHI lauds California state Assembly's proclamation of Feb. 28, as Rare Disease Day

CHI-California Healthcare Institute, a non-profit public policy research organization, applauds the state Assembly’s proclamation of Feb. 28, as Rare Disease Day. This day helps bring awareness of the biomedical companies that are dedicated to researching and developing treatments for patients suffering from rare diseases.

27 Feb 2010

Medical innovation and research: A real boon for American patients to live longer, healthier

An article in the Suislaw News recently highlighted the fact that medical innovation and research are enabling many people to live longer, healthier and more productive lives.

26 Feb 2010

Wound Management Technologies announces recent increase in sales of CellerateRx throughout U.S.

Wound Management Technologies, Inc. announced today that the recent increase in sales activities throughout the United States has resulted in 45 new clinicians evaluating their advanced wound care collagen product, CellerateRx® . In the last two months, these evaluations have transpired into new customers in Arizona, New Mexico, South Carolina, North Dakota, New Jersey, Wyoming, Colorado, and New York.

26 Feb 2010

Helicos BioSciences to demonstrate single molecule sequencing using Helicos Genetic Analysis System

Helicos BioSciences and it’s collaborators will deliver presentations featured at the Advances in Genome Biology and Technology (AGBT) meeting in Marco Island, Florida, from February 24-27, 2010.

26 Feb 2010

Teva Pharmaceutical announces clinical study results of Copaxone in RRMS patients

Teva Pharmaceutical Industries Ltd. today announced the publication of data from the 15-year clinical study with Copaxone® (glatiramer acetate injection), which is the longest prospective and continuous evaluation ever conducted in relapsing-remitting multiple sclerosis (RRMS) patients. The data were published in the February issue of the journal Multiple Sclerosis.

26 Feb 2010

Supelco launches Ascentis Express Peptide ES-C18 HPLC columns

Supelco, a division of Sigma-Aldrich®, announced today the launch of Ascentis Express Peptide ES-C18, a high-speed, high-performance liquid chromatography (HPLC) column based on a new 160 angstrom Fused-Core™ particle design. This column design exhibits very high column efficiency, providing a stable, reversed phase packing with a pore structure and pore size that is optimized for reversed-phase HPLC separations of peptides and polypeptides.

26 Feb 2010

Pall Corporation announces next generation, 96-well AcroPrep Advance filter plates

Pall Corporation, a global leader in filtration, separation and purification, has introduced its next generation 96-well filter plate that delivers consistency and reproducibility in applications, such as neonatal screening and multiplexing. The Pall AcroPrep Advance filter plate employs new design features that provide uniform filtration rates, lowers hold-up volumes and ensures consistent sample/bead recovery from the wells.

From Pall Corporation 26 Feb 2010

Resverlogix commences enrollment in RVX-208 Phase 2 clinical trial for atherosclerosis in ACS patients

Resverlogix Corp. announced today that it has officially activated the first site for the ASSURE 1 trial and commenced enrollment of patients for dosing of RVX-208. ASSURE 1 is the second Resverlogix Phase 2 clinical trial, led by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with acute coronary syndrome (ACS). This preparatory acute coronary syndrome study will ensure that 50 percent of the enrolled patients receive the IVUS (intravascular ultrasound) assessment.

26 Feb 2010

FDA sets new PDUFA action date for exenatide once weekly NDA

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today confirmed that the U.S. Food and Drug Administration (FDA) has set a new Prescription Drug User Fee Act (PDUFA) action date of March 12 for its review of the exenatide once weekly new drug application (NDA).

25 Feb 2010

Adolor announces $14.6M net product sales of ENTEREG for year ended December 31, 2009

Adolor Corporation today reported a net loss of $47.9 million, or $(1.03) per basic and diluted share, for the year ended December 31, 2009, compared to a net loss of $30.1 million, or $(0.65) per basic and diluted share, for the year ended December 31, 2008.

25 Feb 2010

ICON reports net revenues of $227.4M for fourth-quarter 2009

ICON, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the fourth quarter ended December 31, 2009.

25 Feb 2010

Translational Regenerative Medicine Forum in Winston-Salem

A spray-on skin product and an injectable cell therapy for heart attack patients are among 17 regenerative medicine technologies that will be showcased during the Translational Regenerative Medicine Forum, set for April 6-8 in Winston-Salem.

25 Feb 2010

Semafore Pharmaceuticals awarded U.S. patent covering PI-3 kinase inhibitor prodrugs

Semafore Pharmaceuticals today announced today announced the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,662,977 entitled “PI-3 Kinase Inhibitor Prodrugs.” This composition of matter patent covers a genus of novel compounds that includes SF1126, Semafore’s clinical stage, small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival.

25 Feb 2010

LGL awards first three grants from POC fund for research in immunotherapy, schizophrenia and heart disease

London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, has awarded the first three grants from its proof-of-concept (POC) fund. The awards, to teams at Imperial College London and University College London, are for research in the areas of immunotherapy, schizophrenia and heart disease.

25 Feb 2010

Hormone vasopressin helps brain differentiate between familiar and new scents

The study, published in the journal Nature, suggests that when the hormone fails to function, animals are unable to recognise other individuals from their scent.

25 Feb 2010

Advanced ovarian cancer: Avastin-chemotherapy combination followed by Avastin alone improves PFS

Genentech, Inc., a wholly owned member of the Roche Group, today announced that a Phase III study showed the combination of Avastin® (bevacizumab) and chemotherapy followed by maintenance use of Avastin alone increased the time women with previously untreated advanced ovarian cancer lived without the disease worsening (progression-free survival or PFS), compared to chemotherapy alone. A preliminary assessment of safety noted adverse events previously observed in pivotal trials of Avastin.

25 Feb 2010

Anadys Pharmaceuticals' ANA598 combination demonstrates 73% cEVR in ongoing Phase II study for HCV

Anadys Pharmaceuticals, Inc. today announced preliminary results from an ongoing Phase II study demonstrating that 73% of hepatitis C patients treated with 200 mg ANA598 twice daily in combination with pegylated interferon and ribavirin (SOC) achieved undetectable levels of virus (<15 IU/mL) at week 12, known as complete Early Virological Response or cEVR.

25 Feb 2010

MedNet Solutions introduces iMedNet eClinical technology platform

MedNet Solutions, a global life sciences technology solutions company specializing in clinical study management systems, is pleased to announce iMedNet™, the company's ground-breaking new electronic data capture (EDC)/eClinical technology platform.

24 Feb 2010

Life Technologies adds SOLiD PI System to sequencing solutions portfolio

Life Technologies Corporation today announced plans for the Applied Biosystems SOLiD™ PI System, a new highly accurate, flexible and easy-to-use genomic analysis platform that will bring next-generation sequencing within the grasp of all life science research laboratories worldwide. Early customer adoption of the SOLiD PI System is expected to begin in the second half of 2010.

24 Feb 2010

Biotechnology News and Research

iBioLaunch platform technology to be licensed for plant-expressed influenza vaccines project

CHI lauds California state Assembly's proclamation of Feb. 28, as Rare Disease Day

Medical innovation and research: A real boon for American patients to live longer, healthier

Wound Management Technologies announces recent increase in sales of CellerateRx throughout U.S.

Helicos BioSciences to demonstrate single molecule sequencing using Helicos Genetic Analysis System

Teva Pharmaceutical announces clinical study results of Copaxone in RRMS patients

Supelco launches Ascentis Express Peptide ES-C18 HPLC columns

Pall Corporation announces next generation, 96-well AcroPrep Advance filter plates

Resverlogix commences enrollment in RVX-208 Phase 2 clinical trial for atherosclerosis in ACS patients

FDA sets new PDUFA action date for exenatide once weekly NDA

Adolor announces $14.6M net product sales of ENTEREG for year ended December 31, 2009

ICON reports net revenues of $227.4M for fourth-quarter 2009

Translational Regenerative Medicine Forum in Winston-Salem

Semafore Pharmaceuticals awarded U.S. patent covering PI-3 kinase inhibitor prodrugs

LGL awards first three grants from POC fund for research in immunotherapy, schizophrenia and heart disease

Hormone vasopressin helps brain differentiate between familiar and new scents

Advanced ovarian cancer: Avastin-chemotherapy combination followed by Avastin alone improves PFS

Anadys Pharmaceuticals' ANA598 combination demonstrates 73% cEVR in ongoing Phase II study for HCV

MedNet Solutions introduces iMedNet eClinical technology platform

Life Technologies adds SOLiD PI System to sequencing solutions portfolio

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News